Cigarette for electrical smoking system
    2.
    发明授权
    Cigarette for electrical smoking system 失效
    香烟电吸烟系统

    公开(公告)号:US5499636A

    公开(公告)日:1996-03-19

    申请号:US425837

    申请日:1995-04-20

    IPC分类号: A24F47/00 A24B15/12 A24B15/18

    CPC分类号: A24F47/008

    摘要: A novel cigarette adapted for use in an electrical cigarette system comprising a tobacco rod having filled and untilled tobacco rod portions and being arranged so that electrical heater elements may overlap the filled and untilled tobacco rod portions. The tobacco rod includes a tobacco web rolled into tubular form. The tobacco web is constructed in accordance with a novel process comprising the steps of converting tobacco feedstock into a continuous sheet of tobacco web and converting the continuous sheet of tobacco web into one or more bobbins of tobacco web suitable for automated manufacture of cigarettes.

    摘要翻译: 一种适用于电子烟系统的新型香烟,其包括具有填充和未烟草的烟草棒部分的烟草棒,并且布置成使得电加热器元件可以与填充和未烟草的烟草棒部分重叠。 烟草棒包括卷成管状的烟草纤维网。 烟草网根据新的方法构建,该方法包括以下步骤:将烟草原料转化成连续的烟草纤维片,并将烟草纤维网的连续片材转化成适合于自动生产香烟的烟草纤维网的一个或多个筒管。

    System and method for communicating in a time division multiple access (TDMA) mesh network having minimized end-to-end latency
    5.
    发明授权
    System and method for communicating in a time division multiple access (TDMA) mesh network having minimized end-to-end latency 有权
    用于在具有最小化的端到端等待时间的时分多址(TDMA)网状网络中进行通信的系统和方法

    公开(公告)号:US07894416B2

    公开(公告)日:2011-02-22

    申请号:US11620756

    申请日:2007-01-08

    IPC分类号: H04B7/212

    CPC分类号: H04W28/18 H04W28/24 H04W84/18

    摘要: A system and method for communicating includes a plurality of wireless nodes forming a Time Division Multiple Access (TDMA) mesh network. Each wireless node includes a transmitter and receiver and is operative for transmitting data packets across the TDMA mesh network from a source node through intermediate nodes to a destination node using a TDMA epoch such that a slot of channel time is allocated in both time and TDMA epoch prior to a wireless node transmitting the data packet.

    摘要翻译: 用于通信的系统和方法包括形成时分多址(TDMA)网状网络的多个无线节点。 每个无线节点包括发射机和接收机,并且可操作用于使用TDMA时期从TDMA节点从源节点通过中间节点向目的地节点发送数据分组,使得在时间和TDMA时代分配信道时间的时隙 在无线节点发送数据分组之前。

    Process for making adipic acid
    6.
    发明授权
    Process for making adipic acid 失效
    己二酸的制备方法

    公开(公告)号:US07399883B2

    公开(公告)日:2008-07-15

    申请号:US11488197

    申请日:2006-07-17

    IPC分类号: C07C51/15

    摘要: Disclosed in a process for making (1) a compound of the formula NC—CH2—CH2—CH2—CH2—CO2R′, wherein R′ is H or C1 to C12 alkyl, or (2) adipic acid or (3) dimethyl adipate, using as the substrate, 3-pentenenitrile, (2) 3-pentenoic acid or methyl 3-pentenoate, respectively, by contacting the substrate with carbon monoxide and a nucleophile in the presence of a Group VIII metal, a selected ligand, and an acid promoter. The nucleophile, which (a) an alcohol or water, or (b) water or (c) methanol, respectively, in the presence of a Group VIII metal, preferably palladium, a selected phosphine ligand, and an acid promoter.

    摘要翻译: 公开在制备(1)式NC-CH 2 -CH 2 -CH 2 -CH 2的化合物的方法中, 2,其中R'是H或C 1至C 12烷基,或(2)己二酸 酸或(3)己二酸二甲酯,分别使用3-戊烯腈,(2)3-戊烯酸或3-戊烯酸甲酯,通过在第VIII族金属存在下使底物与一氧化碳和亲核试剂接触 ,选择的配体和酸启动子。 在第VIII族金属,优选钯,选择的膦配体和酸促进剂的存在下,分别为(a)醇或水,或(b)水或(c)甲醇)的亲核试剂。

    MD-1 inhibitors as immune suppressants
    7.
    发明授权
    MD-1 inhibitors as immune suppressants 失效
    MD-1抑制剂作为免疫抑制剂

    公开(公告)号:US07291330B2

    公开(公告)日:2007-11-06

    申请号:US10221154

    申请日:2001-03-16

    摘要: Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of an agent that inhibits MD-1 with or without an OX-2 protein or a nucleic acid encoding an OX-2 protein. The methods are useful in preventing graft rejection, fetal loss, autoimmune disease, and allergies. Methods and compositions for preventing immune suppression are also disclosed. The methods involve administering an effective amount of MD-1 or an agent that activates or stimulates MD-1.

    摘要翻译: 公开了诱导免疫抑制的方法和组合物。 所述方法包括施用有效量的抑制具有或不含OX-2蛋白的MD-1或编码OX-2蛋白的核酸的试剂。 该方法可用于预防移植物排斥,胎儿丧失,自身免疫性疾病和过敏。 还公开了用于预防免疫抑制的方法和组合物。 所述方法包括施用有效量的MD-1或激活或刺激MD-1的药剂。